Oxford Biomedica Share Price (OXB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Oxford Biomedica	LSE:OXB	London	Ordinary Share	GB0006648157	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.02p	-0.13%	14.96p	14,401,590	16:35:23
Bid Price		Offer Price	High Price	Low Price	Open Price
14.86p		14.94p	15.10p	14.84p	14.98p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	37.6	-11.8	-0.3	-	491.24

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Oxford Biomedica (OXB) Latest News

Oxford Biomedica News

Date	Time	Source	Headline
23/5/2018	13:41	UKREG	Oxford Biomedica PLC Director Dealings / Market Share Purchase
04/5/2018	11:57	ALNC	Oxford BioMedica To Cut Share Capital Through Consolidation (ALLISS)
04/5/2018	07:43	ALNCF	Alliance News Flash Headline
04/5/2018	07:00	UKREG	Oxford Biomedica PLC Proposed Share Capital Consolidation
02/5/2018	17:35	ITALNC	Partner di Novartis Oxford BioMedica ottiene approvazione per Kymriah
02/5/2018	11:57	ALNC	Oxford BioMedica Partner Novartis Gets FDA Approval For Kymriah
02/5/2018	07:00	UKREG	Oxford Biomedica PLC Kymriah receives FDA approval for DLBCL
01/5/2018	09:37	UKREG	Oxford Biomedica PLC Total Voting Rights
26/4/2018	15:33	UKREG	Oxford Biomedica PLC Holding(s) in Company
26/4/2018	07:30	UKREG	Oxford Biomedica PLC 2017 Annual Report and Accounts & AGM Notification

More Oxford Biomedica News

Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Share Charts

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date	Time	Title	Posts
24/5/2018	18:42	Feck off the_doctor	149
24/5/2018	18:15	Oxford Biomedica Bulls Only Thread	30,488
23/5/2018	18:09	The hypocrites thread	43
23/5/2018	16:50	Oxford Biomedica - the_doctor free thread	340
21/5/2018	22:16	OXB-doc-free thread	2

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
16:15:00	15.07	1,596,639	240,629.46	O
15:57:16	15.00	18,100	2,714.37	O
15:35:23	14.96	10,543	1,577.23	O
15:35:23	14.96	322,517	48,248.54	UT
15:29:30	14.94	415	62.00	AT

View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Date	Subject
24/5/2018 09:20	Oxford Biomedica Daily Update: Oxford Biomedica is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 14.98p. Oxford Biomedica has a 4 week average price of 11.60p and a 12 week average price of 10.22p. The 1 year high share price is 15.50p while the 1 year low share price is currently 4.91p. There are currently 3,283,687,286 shares in issue and the average daily traded volume is 7,508,143 shares. The market capitalisation of Oxford Biomedica is £491,239,617.99. Read Full Thread Reply
13/4/2018 21:58	beanol: It really is getting boring Pram. For example the idea that Oxb Directors buying shares in the way they have been doing recently is going to help boost the Oxb share price in the short term is almost certainly for the birds. The last time they did this was to help support the share price when (in retrospect) no good news was in prospect. And the share price fell significantly over a long period of time. Much better i suggest to consider the Doc as a contributor whose posts are sometimes much needed if unwelcome but that some go over the top and need correcting. For example Doc's attacks on Marcus and Harry are often just out of order and some of us call them out. But for f's sake just leave some of your bad ill tempered irrelevant postings out. That is not to say that we and I in particular don't value most of your posts. They are largely flipping great. And your connectivity to the senior management of Oxb often gives us insights that would otherwise be denied us. Read Full Thread Follow Reply
22/2/2018 13:14	luxsuspick: Breaking Down Oxford BioMedica PLC’s (LON:OXB) Ownership Structure Erna Eldridge February 22, 2018 I am going to take a deep dive into Oxford BioMedica PLC’s (LSE:OXB) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. Differences in ownership structure of companies can have a profound effect on how management’s incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. Although this is an important factor for long-term investors, many investors can also be impacted by institutional presence and their high-volume trading. Therefore, I will take a look at OXB’s shareholders in more detail. Check out our latest analysis for Oxford BioMedica LSE:OXB Ownership_summary Feb 22nd 18 LSE:OXB Ownership_summary Feb 22nd 18 Institutional Ownership OXB’s 68.26% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. These moves, at least in the short-term, are generally observed in an institutional ownership mix comprising of active stock pickers, in particular levered hedge funds, which can cause large price swings. With hedge funds holding a 18.72% stake in the company, its share price can experience heightened volatility. But I also examine other ownership types and their potential impact on OXB’s investment case. Insider Ownership Insiders form another group of important ownership types as they manage the company’s operations and decide the best use of capital. Insider ownership has been linked to better alignment between management and shareholders. Although individuals in OXB hold only a 3.79% stake, it’s a good sign for shareholders as the company’s executives and directors have their incentives directly linked to the company’s performance. In addition to this, it may be interesting to look at insider buying and selling activities. Keep in mind that buying may be sign of upbeat future expectations, but selling doesn’t necessarily mean the opposite as the insiders might just be doing it out of their personal financial needs. LSE:OXB Insider_trading Feb 22nd 18 LSE:OXB Insider_trading Feb 22nd 18 General Public Ownership With 6.23% ownership, the general public are also an important ownership class in OXB. This size of ownership, while considerably large for a public company, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private Company Ownership Another group of owners that a potential investor in OXB should consider are private companies, with a stake of 2.82%. While they invest more often due to strategic interests, an investment can also be driven by capital gains through share price appreciation. However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence OXB’s business strategy. Thus, investors not need worry too much about the consequences of these holdings. Next Steps: I suggest investors seek some degree of margin of safety due to high institutional ownership in OXB, in particular due to the strong presence of active hedge fund investors. This may enable shareholders to comfortably invest in the company and avoid getting trapped in a sustained sell-off that is often observed in stocks with this level of institutional participation. However, if you are building an investment case for OXB, ownership structure alone should not dictate your decision to buy or sell the stock. Instead, you should be evaluating company-specific factors such as Oxford BioMedica’s past track record and financial health. I highly recommend you to complete your research by taking a look at the following: 1. Future Outlook: What are well-informed industry analysts predicting for OXB’s future growth? Take a look at our free research report of analyst consensus for OXB’s outlook. 2. Past Track Record: Has OXB been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of OXB’s historicals for more clarity. 3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Want to know why the market is moving Read Full Thread Follow Reply
14/2/2018 15:57	old sage: Gareth Jones Don't know if there's ever a good time , to be a LTH (unless you got into OXB at circa 3 pence and are holding on for 30 pence. However with the future looking promising, anyone with an interest in OXB should, (as HST alluded to, earlier ) hang on in there. The prospects have never been better for the OXB share price, over the last two decades. GLA Read Full Thread Follow Reply
05/12/2017 17:49	scrutable: There is such a dog fight over clinical details and egos on this board, that non technical people must have lost sight of the fundamentals which affect the OXB share price. It has exhibited an ever more dampened sideways oscillation and fails to reflect the great furore over the prospects for CAR-T therapy repeated in the global Press, Conferences and video broadcasting, since July. I am irritated by failing to be able to turn up an influential article in the European edition of the NY Times, quoting JD several times and OXB by name that I read a week or so ago. The gist was that authorisation to manufacture the virus vector in cell therapy is excrutiatingly difficult to earn, and that there is a currently irremediable shortage of the product putting OXB in a lead position with more potential drug developer clients than can be supplied for years. Only this can explain the fairly unusual contract they were able to close with Novartis. Would be purchasers are jostling each other for access to the few adequately structured suppliers Most of those who have tried to establish an in-house supply have wasted years and failed. One such company acquired a recipe and IP, but after 18 months had failed to produce anything at all of use due to a very small error controlling the exact acidity of the supply, which was killing the viral vector. There is no short cut to displacing OXB as a main supplier. The technology and process detail, and the control procedures, the staff trained and trusted to apply them, agreement details and signatures required cannot be established in under 2-3 years. So why have investors failed to take the basics of supply and demand into consideration. Read Full Thread Follow Reply
13/9/2017 10:33	graham101: Thanks for the replies. I realise that the share price has gone up dramatically in the last year. However, when the Novartis FDA approval came through, I would have expected OXB share price to go even higher, which is why I bought in. It has dropped back quite a bit since then and that is what I can't understand. The other reason I bought is because I think the future use for the treatments is astounding if all goes to plan. Fortunately, I bought some KITE two weeks before the GILD take-over was announced so had a great return in a very short time. Just luck though. I really hope these treatments are successful as it could transform so many lives. Read Full Thread Follow Reply
05/9/2017 13:08	prambigear: This news is not helping the Novartis or OXB share prices, it should because it lengthens the time where we have the market, but I guess investors do not know the difference between our CAR-T treatment and an allogeneic CAR-T. the_doctor does. But presumably he is doing something else.... Read Full Thread Follow Reply
13/7/2017 14:32	stocktastic: 'As for the IPO, a pet subject of yours, I can't think of a better example showing that when you raise something which is plainly tripe' Here is the basis for my speculation: - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. No honest poster would call that 'tripe' So you just think it's a coincidence that most/all of the directors bought relatively small quantities of stock around the highs? You think OXB would be paying high rates of interest if they could have taken a rare opportunity to tap the US markets? Coincidence that OXB announced a fundraiser that included a private placing in the US, shortly after my IPO-failed speculation? My view on that was that they were making the most of parties that had become interested through a US listing attempt It's actually all quite plausible. Certainly no need to call it tripe Read Full Thread Follow Reply
11/7/2017 14:01	stocktastic: 'revisionist history' eh? Nothing revised there 'I must remember that escape for future reference - claim the other person raised it first' You're perhaps misinterpreting as I didn't do that at all.. Re IPO theory - I just reiterated it is MY opinion, but asked whether OXB could confirm it to be wrong when I speculate they tried to list in the US Then I said that I disagree with your view that they'd not be able to afford a US listing - since as explained, half the purpose of listing would be to raise cash. So where's the 'escape' and claiming someone else raised it first??? Look at my US listing theory this way - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. So you're suggesting that the company took on loans at a high rate of interest rather than try and capitalise on a rare opportunity to list in the US on great terms? It actually seems rather unlikely to me that OXB didn't try to list in the US IMO the reason the company failed was the early stage of products, the past failures and the lower appetite for manufacturing/royalies vs more traditional biotech listings etc. Read Full Thread Follow Reply
06/7/2017 14:28	asat91: As I understand it, OXB are spending £40mill per year at the moment, and their revenue is about 20-30mill without CTL019. So if they make the £65mill/year estimated from CTL019, and maintain their current revenue and costs this would give a pre-tax profit of about £40mill/year. Earnings per share in that situation would be 40mill/3billion = 0.013. P/E ratio at current share price would be 7.5, which as marcus says would be very low for a promising biotech company in oncology gene therapy, especially a biotech company that is so valuable to a giant like Novartis. Expect a P/E ratio of between 15 and 25 by December 2017 or by December 2018 when they release their profits (assuming approval and sales of CTL019) which would give a share price of 25p+. Better investment than any bank account that's for sure! Even if we will have to wait until Dec 18 for the profit statement after CTL019 has been selling a while. And of course with good news coverage, positive broker reports and popularity comes market hysteria which could even push the share price up to something ridiculous like 40p or 50p at some point next year. I wasn't around for Trovax but I assume that's what happened there? If Novartis do decide to buy/acquire OXB at some point over the next year or two, we could be looking at a sale price of close to £1billion which Novartis can easily afford with cash reserves of £14billion+, and would be more than 3x current OXB share price. What do you guys think? Read Full Thread Follow Reply
02/7/2017 18:54	gareth jones: I fear for the OXB share price in the morning given all this good news! Seriously we should see good volume and hopefully a positive share price leading up to the FDA meeting on 12th. If we dont get an announcement/decision on 12th we may see a draw back as short termers have to bail out but it should make little difference to all LTH's. MM's will earn their money in the next couple of weeks as they respond to market sentiment and demand in setting buy/sell prices. Read Full Thread Follow Reply

Oxford Biomedica share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:33 V: D:20180524 18:00:04